HCC's Hematological Malignancies Program provides comprehensive therapy for a broad range of disorders, including: - Acute and chronic leukemias
- Myelodysplastic Syndrome (MDS)
- Hodgkin's Lymphoma
- Non-Hodgkin's lymphoma
- Myeloma
Outpatient focus - For our patients' health and convenience, we limit their stay in the hospital, shifting them to an outpatient setting as soon as possible. Our state-of-the-art infusion center and home infusion services, staffed only with nurses certified by the Oncology Nursing Society, make outpatient treatment a reality for many patients. Clinical trials - Patients have access to clinical trials for promising new therapies. The goal of these research efforts is to bring effective new treatments to patients as quickly as possible. Don't hesitate to discuss clinical trials with your medical team. Highlights include:
· Nation’s number one accruing site for SWOG 0106: Patients Under Age 56 with Previously Untreated DeNovo Acute Myeloid Leukemia (AML). We have a 91% complete remission rate. · Lead institution for a “first-in-class” agent: (Phase I/II Study of AS1411 Combined With Cytarabine For Patients With Primary Refractory Or Relapsed Acute Myeloid Leukemia). · National commendation for participation in CALGB 10201: Previously Untreated Patients with Acute Myeloid Leukemia (AML) >= 60 Years. Our complete remission rate was 70% compared to 50% for all sites. Read more about clinical trials.
State-of-the-art facilities - In addition to innovative outpatient facilities, our inpatient unit is technologically- advanced. The rooms were specially designed for immunosuppressed patients and use the same sophisticated HEPA air filtration system found in our operating rooms. Housing assistance - If your stay here is extended, our staff can help you find local housing in all budget ranges. | 
